Drugs / JE-VAX®
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy6 trials | ||||||
| Phase 2 | NCT02816554 Comparator | Apr → Sep 2015 | Japanese encephalitis | National Institute of Hygiene and Epidemiology, Vietnam | Completed | No outcome recorded |
| Phase 2 | NCT00740155 Comparator | Aug 2008 → Oct 2009 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00319592 Comparator | May 2005 → Sep 2006 | Japanese encephalitis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03282370 Comparator | Sep 2017 → Feb 2018 | Japanese encephalitis | National Institute of Hygiene and Epidemiology, Vietnam | Completed | No outcome recorded |
| Phase 3 | NCT00314145 Comparator | Nov 2005 → Jun 2006 | Japanese encephalitis | Sanofi | Completed | Met primary |
| Phase 3 | NCT00604708 Comparator | Sep 2005 → Sep 2006 | Japanese encephalitis | Valneva Austria GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JE-Vax | “0.5 mL, Subcutaneous (JE-Vax®); 1.0 mL, (Saline)” NCT00314145 ↗ |
| Modality | Vaccine | “JE-VAX® vaccine” NCT00314145 ↗ |
| Route | Subcutaneous | “0.5 mL, Subcutaneous (JE-Vax®)” NCT00314145 ↗ |